Point Roberts, WA, Delta BC – April 21, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors following the sector.
Australian listed (ASX) stocks are at the forefront of this week’s additions with 4 new stocks being added that include a company involved in medical cannabis for treatment of a variety of ailments; a cannabis-based medicine for oncology; cannabidiol treatment for psoriasis and atopic dermatitis and Creso Pharma Limited (ASX:CPH.AX) a leader in cannabidiol (CBD) innovation, currently developing cannabis and hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis products with a broad range of applications in both human and animal health.
Also new this week are Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company who recently completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a unique suite of standardized and commercialized products for the medical cannabis market and Stereo Vision Entertainment, Inc. (OTC:SVSN) a media company who is also the majority owner of medical cannabis and organic hemp subsidiary, MediCannaVision Inc., dba CannaVision.
Investorideas.com cannabis/marijuana and hemp content now includes: http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
New Marijuana Companies Added to the Investor cannabis stock directory:
Botanix Pharmaceuticals Ltd. (ASX:BOT.AX) mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. We are harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Creso Pharma Limited (ASX:CPH.AX) pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products, leveraging science and research in order to develop, register and commercialise innovative therapeutic approaches targeting the endocannabinoid system. Creso Pharma is a leader in cannabidiol (CBD) innovation, developing cannabis- and hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis products with a broad range of applications in both human and animal health. Creso Pharma’s innovative CBD fully plant-based nutraceutical products are non-psychoactive, as they contain only trace amounts of THC. Focusing on unique and innovative product delivery systems, Creso Pharma is developing therapeutic products and nutraceuticals manufactured according to the highest GMP standards, and maintaining the highest levels of compliance across the supply chain. Creso Pharma holds worldwide rights for a number of proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. Furthermore, Creso Pharma’s standardised dosage forms are specifically designed and adapted for human health and for animal health, and for several medical conditions including pain and anxiety disorders, metabolic disorders and inflammatory disorders.
Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI. Cannabis: Completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a unique suite of standardized and commercialized products for the medical cannabis market
Medlab Clinical Ltd. (ASX:MDC.AX) l is an Australian based medical life science company, with a certified biologics facility in Sydney and sales arms in Australia and California. Medlab’s research relates to five health areas – obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. A lot of Medlab’s research is on the role bacteria in the gastrointestinal tract play in health and disease, leading to drug discovery and development of new medicines involving bacteria (pharmacobiotics) as well as nutritional products. Medlab is also about to commence a human trial of a cannabis-based medicine for oncology patients with intractable pain, utilising its small particle medicine delivery system, Nanocelle™. Medlab has a growing patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.
Stereo Vision Entertainment, Inc. (OTC:SVSN) is a publicly traded Nevada company focused on creating, acquiring, and producing multimedia content with its media subsidiaries the majority owned family entertainment company Inspirational Vision Media and the wholly owned 9 time Emmy Award winning production company REZN8, and the majority owned medical cannabis and organic hemp subsidiary, MediCannaVision Inc., dba CannaVision.
Zelda Therapeutics Limited (ASX:ZLD.AX) has been formed to bring together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.
The complete marijuana/hemp stock list available for purchase in a PDF format:
Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector. Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.
Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format. The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com – News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.
Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Services for Publicly traded and private companies: http://www.investorideas.com/Investors/Services.asp
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Source: New feed